Connection

CHRISTINE BEETON to Potassium Channel Blockers

This is a "connection" page, showing publications CHRISTINE BEETON has written about Potassium Channel Blockers.
Connection Strength

3.419
  1. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 07; 180:45-57.
    View in: PubMed
    Score: 0.540
  2. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011 Oct; 10(5):313-21.
    View in: PubMed
    Score: 0.369
  3. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.
    View in: PubMed
    Score: 0.232
  4. [Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers]. Rev Neurol (Paris). 2004 May; 160(5 Pt 2):S16-27.
    View in: PubMed
    Score: 0.221
  5. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2211977120.
    View in: PubMed
    Score: 0.201
  6. Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis. J Pharmacol Exp Ther. 2018 05; 365(2):227-236.
    View in: PubMed
    Score: 0.143
  7. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Sci Rep. 2017 06 16; 7(1):3756.
    View in: PubMed
    Score: 0.137
  8. N-Terminally extended analogues of the K? channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J. 2015 Jun; 282(12):2247-59.
    View in: PubMed
    Score: 0.118
  9. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep; 28(9):3952-64.
    View in: PubMed
    Score: 0.111
  10. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep. 2014 Mar 28; 4:4509.
    View in: PubMed
    Score: 0.110
  11. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.109
  12. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One. 2013; 8(11):e78712.
    View in: PubMed
    Score: 0.107
  13. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013; 8(10):e76740.
    View in: PubMed
    Score: 0.106
  14. Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers. PLoS One. 2012; 7(12):e52965.
    View in: PubMed
    Score: 0.100
  15. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 2012 Nov 16; 586(22):3996-4001.
    View in: PubMed
    Score: 0.099
  16. Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. Toxicon. 2012 Oct; 60(5):840-50.
    View in: PubMed
    Score: 0.097
  17. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep; 82(3):372-82.
    View in: PubMed
    Score: 0.096
  18. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol. 2009 Apr; 75(4):762-73.
    View in: PubMed
    Score: 0.076
  19. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29(4):602-14.
    View in: PubMed
    Score: 0.075
  20. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17414-9.
    View in: PubMed
    Score: 0.066
  21. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun; 65(6):1364-74.
    View in: PubMed
    Score: 0.055
  22. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004 May; 25(5):280-9.
    View in: PubMed
    Score: 0.055
  23. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003 Sep; 6(5):640-7.
    View in: PubMed
    Score: 0.053
  24. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13942-7.
    View in: PubMed
    Score: 0.047
  25. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001 Jan 15; 166(2):936-44.
    View in: PubMed
    Score: 0.044
  26. KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis. Arthritis Rheumatol. 2015 Jan; 67(1):96-106.
    View in: PubMed
    Score: 0.029
  27. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther. 2012 Sep; 342(3):642-53.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.